FindTrial
Sign In

Paclitaxel protein bound

DRUG2 trials

Sponsors

Barts & The London NHS Trust, HonorHealth Research Institute

Conditions

Borderline Resectable Pancreatic AdenocarcinomaLocally Advanced Pancreatic AdenocarcinomaPancreatic CancerUntreated Resectable Pancreatic Adenocarcinoma

Phase 2

Paricalcitol Addition to Chemotherapy in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
CompletedNCT04054362
Barts & The London NHS TrustPancreatic Cancer
Start: 2018-11-29End: 2025-02-08Updated: 2025-11-21
Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydroxychloroquine as Treatment in Untreated Pancreas Cancer
CompletedNCT04669197
HonorHealth Research InstituteBorderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma, Untreated Resectable Pancreatic Adenocarcinoma
Start: 2020-12-01End: 2025-07-31Updated: 2026-07-21

Related Papers

Abstract A048: Paricalcitol improves survival in tumor-permissive cancer-associated fibroblast subtype of pancreatic cancers
Cancer Research2024-09-15
Abstract CT214: Paricalcitol addition to chemotherapy in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PINBALL)
Cancer Research2024-04-052 citations
Paclitaxel protein bound (A) plus gemcitabine (G) plus cisplatin (C) and hydroxychloroquine (HCQ) neoadjuvant therapy for localized pancreatic ductal adenocarcinoma (PDAC).
Journal of Clinical Oncology2024-01-20